Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs.
It is a $173B healthcare company. Revenue grew 8.1% over the last year, it keeps 12¢ of every dollar of sales as profit, and its net debt equals ~0.1 years of free cash flow. It trades at 31.8× earnings — around the middle of its own history.
- Website
- abbott.com
- Location
- Abbott Park, IL
- Employees
- 115 000
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong health and quality; Growth lags behind.
Valuation56
- P/E vs own history56th pct · 12/25
- FCF yield4.5% · 12/25
- P/S3.7x · 20/25
- EV/EBITDA21.5x · 12/25
Growth43
- Revenue CAGR0.7% · 6/25
- Net income CAGR-2.0% · 0/25
- EPS CAGR ~5Y8.2% · 12/25
- Fwd implied growth81.0% · 25/25
Profitability64
- ROIC12.3% · 12/25
- ROE10.5% · 12/25
- Net margin11.6% · 20/25
- Operating margin15.8% · 20/25
Health75
- Altman Z2.84 · 18/25
- Current ratio1.38 · 12/25
- Interest coverage63.7x · 25/25
- Net cash / debtD/A 1% · 20/25
Quality87
- Piotroski F7/9 · 22/25
- Beneish M-2.49 · 20/25
- FCF conversion144% · 25/25
- Margin stabilityσ 5.3% · 20/25
Moat62
- ROIC >12% years2/10 yrs · 0/25
- Median gross margin56.5% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 1.7% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2025AcquisitionAbbott announced an agreement to acquire Exact Sciences Corp
- FY2024FinancialBest year on record$13.4B net income
- 2020MilestoneThe Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve…
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $10B$20.9B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2014AcquisitionIt was announced that Abbott would acquire the holding company Kalo Pharma Internacional S.L
- 2010AcquisitionAbbott acquired the pharmaceuticals unit of Solvay S.A
- 2009AcquisitionAbbott acquired Advanced Medical Optics of Santa Ana, California, selling it to Johnson & Johnson in 2017
- 2007AcquisitionAbbott acquired Kos Pharmaceuticals for $3.7 billion in cash
- 2007MilestoneAbbott's Ross Products was renamed Abbott Nutrition in 2007
- 2004MilestoneAbbott completed the corporate spin-off of Hospira, its hospital products division
- 2004AcquisitionIt acquired TheraSense, a diabetes-care company, which it merged with its MediSense division to become…
- 2001AcquisitionThe company acquired Knoll, the pharmaceutical division of BASF, for $6.9 billion
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (56.8%)
- Strong cash conversion — FCF is 16.8% of revenue
- Interest covered 63.7× by operating earnings
- Piotroski F-Score 7/9 — fundamentally strong checklist
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.1% YoY
- Profitable — makes more than it spends$5.42B TTM
- Profit growing — earnings are higher than last year-1.7% YoY
- Generates cash — cash left after running and investing$7.82B TTM
- Debt under control — could handle its obligations~0.1y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$173B market cap
- Not printing shares — share count not ballooning — you keep your slice-2.1% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.8 — grey
- Pays a dividend — returns cash to shareholdersyield 2.47%
- Valuation not extreme — price not wildly above earningsP/E 31.8
Peer comparisonAbbott Laboratories vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ABT this company | $172.7B | 31.8 | +8.1% | 11.6% | Solid |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ABT vs LLY · ABT vs JNJ · ABT vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ABT
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ABT on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $99.78 · market cap $173B.